KEY FEATURES
| Full Name | Macrophage Inflammatory Protein 3 Beta |
|---|---|
| Synonym | CCL19; CKb11; ELC; MIP3-B; SCYA19; Chemokine C-C-Motif Ligand 19; Beta Chemokine Exodus-3; CK Beta-11; EBI1-Ligand Chemokine; Small Inducible Cytokine Subfamily A19 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 15.6-1000pg/mL |
| Sensitivity | 6.2pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human MIP3b in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human MIP3b. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human MIP3b and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human MIP3b, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human MIP3b. You can calculate the concentration of Human MIP3b in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES
TYPICAL DATA
Human MIP3b ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 49.96 | 158.19 | 394.18 | 47.46 | 162.72 | 406.92 |
| Standard deviation | 3.11 | 7.47 | 16.16 | 2.88 | 8.87 | 20.1 |
| CV(%) | 6.23 | 4.72 | 4.1 | 6.07 | 5.45 | 4.94 |
RECOVERY
The recovery of Human MIP3b spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 88-105 | 96 |
| EDTA plasma (n=8) | 95-108 | 101 |
| Cell culture media (n=8) | 90-106 | 96 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human MIP3b in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.
Products associated with CCL19 ELISA Kits
| CCR7 ELISA Kit | publications with CCL19 and CCR7 |
| CXCL13 ELISA Kit | publications with CCL19 and CXCL13 |
| CXCL10 ELISA Kit | publications with CCL19 and CXCL10 |
| CCR5 ELISA Kit | publications with CCL19 and CCR5 |
| CCR6 ELISA Kit | publications with CCL19 and CCR6 |
| CXCL9 ELISA Kit | publications with CCL19 and CXCL9 |
| CXCR5 ELISA Kit | publications with CCL19 and CXCR5 |
| CCL25 ELISA Kit | publications with CCL19 and CCL25 |
| CCR1 ELISA Kit | publications with CCL19 and CCR1 |
| CXCL11 ELISA Kit | publications with CCL19 and CXCL11 |
Pathways associated with CCL19 ELISA Kit
| Chemokine Receptors Bind Chemokines Pathway | Chemokine Receptors Bind Chemokines Pathway |
| Chemokine Signaling Pathway | Chemokine Signaling Pathway |
| Class A/1 (Rhodopsin-like Receptors) Pathway | Class A/1 (Rhodopsin-like Receptors) Pathway |
| Cytokine-cytokine Receptor Interaction Pathway | Cytokine-cytokine Receptor Interaction Pathway |
| Defective ACTH Causes Obesity And Pro-opiomelanocortinin Deficiency (POMCD) Pathway | Defective ACTH Causes Obesity And Pro-opiomelanocortinin Deficiency (POMCD) Pathway |
| Disease Pathway | Disease Pathway |
| G Alpha (i) Signalling Events Pathway | G Alpha (i) Signalling Events Pathway |
| GPCR Downstream Signaling Pathway | GPCR Downstream Signaling Pathway |
Diseases associated with CCL19 ELISA Kit
| Inflammation | publications with CCL19 and Inflammation |
| Necrosis | publications with CCL19 and Necrosis |
| Lung Diseases | publications with CCL19 and Lung Diseases |
| Vascular Diseases | publications with CCL19 and Vascular Diseases |
| Hypersensitivity | publications with CCL19 and Hypersensitivity |
| Death | publications with CCL19 and Death |
| Lung Neoplasms | publications with CCL19 and Lung Neoplasms |
| Respiratory Tract Infections | publications with CCL19 and Respiratory Tract Infections |
| Liver Diseases | publications with CCL19 and Liver Diseases |
| Heart Diseases | publications with CCL19 and Heart Diseases |
Organs/Tissues associated with CCL19 ELISA Kit
| Lymph Node | publications with CCL19 and Lymph Node |
| Vascular | publications with CCL19 and Vascular |
| Spleen | publications with CCL19 and Spleen |
| Lung | publications with CCL19 and Lung |
| Thymus | publications with CCL19 and Thymus |
| Brain | publications with CCL19 and Brain |
| Intestine | publications with CCL19 and Intestine |
| Eye | publications with CCL19 and Eye |
| Pancreas | publications with CCL19 and Pancreas |
| Heart | publications with CCL19 and Heart |
